The XBI has plunged 27% since Donald Trump won the election, leaving the public markets an ugly mess for a biotech industry ...

Roche plans $50B investment in US over 5 years for R&D and manufacturing, including 4 new facilities and expansions, amid ...

AstraZeneca/Daiichi's Enhertu plus Perjeta shows better progression-free survival vs standard care in first-line HER2+ ...

Chinese biotech HuidaGene reports early success with first CRISPR brain treatment in 9-year-old with MECP2 duplication ...

Gilead's antibody-drug conjugate Trodelvy combined with Merck's Keytruda reduced the risk of disease progression or death in ...

Alvogen plans to fight a court decision that could significantly delay its ability to bring a generic version of Bausch ...

The FDA made two de­ci­sions on Re­gen­eron’s best-sell­ing drugs Fri­day, hand­ing down one ap­proval and one re­jec­tion.

Roivant is changing its strategy for Immunovant roughly a month after its subsidiary decided it wouldn’t take one of its ...

Sanofi is teaming up with a private biotech in Delaware on a pair of bispecific antibodies for autoimmune and inflammatory ...

US brand-name drugs use foreign ingredients, with Europe supplying 43% of APIs, as Trump administration considers 25% tariffs ...

A hot antibody discovery team in China has signed its second US biotech deal in less than six months, marking the latest sign ...

The 340B drug discount program may move under the purview of CMS, according to a leaked HHS restructuring document reviewed ...